U.S. Asthma Therapies Markets Growing Penetration of Combination Drugs Spur Growth “The tremendous success of bronchodilator/-corticosteroid combination drugs will continue to drive growth in the asthma market, leaving single- agent therapies with limited growth opportunities to exploit throughout the forecast period” Pharmaceutical Biotech Analyst Team Frost & Sullivan

Growing Patient Penetration of Combination Drugs Growing Acceptance of Dry Powder Inhaler Delivery Systems Development of Innovative Pulmonary Delivery Systems Industry Trends

Frost & Sullivan provides: Detailed insights into recent developments and trends Drivers, restraints, challenges, and strategic recommendations Analyst insights on ‘hot topics’ and emerging applications in the U.S. Asthma Therapies Markets Market sizing and competitive analysis Market forecasts and market share analysis Pricing analysis Product, vendor and end user analysis Key Features

Coverage: The United States Proven methodology encompassing extensive primary and secondary data and research Focused information and strategies that cover business and technology issues Credible data and analysis highlighting industry dynamics Winning strategies to help you create precise business plans What We Offer

Current Market Participants Find out how you compare to the competition Assess current and future drivers and restraints Determine and exploit new market share opportunities New Entrants Analyze challenges associated with the industry Calculate time scales for strategy implementation Position yourself to capitalize on the market’s unmet needs Investment Community Analyze long-term strategies of companies in the asthma therapies markets Determine which participants will outperform the competition Assess attractiveness of investing in the asthma therapies markets Who Will Benefit?

Bronchodilators, subdivided into: Short-Acting Beta2 Agonists Long-Acting Beta2 Agonists Anticholinergics Methylxanthines Anti-Inflammatories, subdivided into: Inhaled Corticosteroids Anti-Leukotrienes Mediator-Release Inhibitors Other Emerging Anti-Inflammatory Therapeutics Bronchodilator/Corticosteroid Combinations Other Emerging Asthma Therapies What’s Included

Key Market Participants 3M Pharmaceuticals aaiPharma Abbott Laboratories Alpharma Apotex Corp. AstraZeneca Pharmaceuticals Aventis Pharmaceuticals, Inc. Boehringer Ingelheim Dey, Inc. Forest Laboratories, Inc. GlaxoSmithKline Impax Labs Inspire Pharmaceuticals Inwood Pharmaceuticals Ivax Pharmaceuticals, Inc. King Pharmaceuticals, Inc. Merck & Co., Inc. Morton Grove Pharmaceuticals Novartis Pharmaceuticals Purdue Pharmaceuticals Roxane Laboratories Savage Laboratories Schering-Plough Sepracor, Inc. Sheffield Pharmaceuticals Teva Pharmaceuticals UCB Pharma Wallace Pharmaceuticals Warrick Pharmaceuticals

Call toll free 877 G O F ROST ( ) Fax toll free Visit For More Information